Study summary
An anti-tau antibody was well tolerated and cut free tau in spinal fluid by about 80%
80.41%reduction in free tau in spinal fluid
What was tested
Bepranemab, an antibody that binds the middle region of the tau protein, given by infusion every 4 weeks for 52 weeks, against placebo, in PSP.
What they found
- Side effects and discontinuations were similar to placebo.
- Free tau in spinal fluid fell by 80.41%, showing the antibody reached its target.
- The trial was too small to test whether it slows the disease.
What it means
Earlier anti-tau antibodies targeting the end of the protein failed in PSP; mid-region antibodies like bepranemab are a different approach.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.